Click image to view it in full size

An increasing focus on biologics, genomics, and multi-omics; the adoption of digital technologies; and a shift to patient-centric models are transforming the life sciences industry. At the same time, the emergence of value-based models, R&D activities to treat complex diseases, and healthcare consumerism provide an impetus to precision medicine. In addition, the COVID-19 pandemic has underscored the need for equanimity in access to diagnostics and renewed focus on direct-to-patient, decentralized diagnostics products as well as digital continuity, all of which centre the patient. In this Outlook, Frost & Sullivan identifies the 10 top growth opportunities for the global life sciences and diagnostics industry in 2023.